Nanosphere Announces Distribution and Collaboration Agreement With Hitachi High-Technologies Corporation

Nanosphere Announces Distribution and Collaboration Agreement With Hitachi High-Technologies Corporation 
NORTHBROOK, IL -- (Marketwired) -- 05/13/13 --  Nanosphere, Inc.

--  Hitachi High-Technologies Corporation Provides Distribution Network to
    Market the Verigene System in Japan's High Growth Molecular Diagnostic
--  Collaboration Leverages Each Companies' Advanced Design, Development
    and Manufacturing Expertise for Future Assays and Platforms

Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and
commercialization of advanced molecular diagnostics systems,
announced today it has signed a distribution and collaboration
agreement with Hitachi High-Technologies Corporation (Hitachi
High-Tech). The agreement grants Hitachi High-Tech exclusive rights
to market Nanosphere products in Japan. As well, the two companies
intend to collaborate on assay and platform development. 
The partnership plays a significant role in Nanosphere's global
distribution strategy, as it expands the Company's product reach into
one of the largest healthcare markets in the world. 
"Nanosphere's portfolio of molecular diagnostics tests fits well with
Japan's demand for rapid and accurate diagnostic tools to fight
infections, enabling clinicians to target therapies potentially
improving critical patient care and outcomes," said Kazuhiro
Matsumura, Hitachi High-Tech's General Manager, Medical Systems
Business Development Department, Strategic Planning Division, Science
& Medical Systems Business Group. Mr. Matsumura added, "Nanosphere's
rapid sample-to-result Verigene System meets the needs of Japan's
health care providers who have been waiting for a molecular platform
accessible to hospitals of all sizes." 
"We are very pleased to be partnering with Hitachi High-Tech given
their experience and reputation in both marketing and developing
diagnostic products," said Michael McGarrity, Nanosphere's president
and chief executive officer. "Hitachi High-Tech has a world class
reputation for excellence and quality worldwide, and we jointly
believe there is a considerable market and value creation opportunity
that will be realized through this collaboration." 
Benefits of Nanosphere's Growing Menu of Infectious Disease Products 
e need for rapid, accurate and clinically actionable diagnostic
results has been well defined in Europe and the USA with Nanosphere's
broad menu of infectious disease tests: 

--  Gram-Positive Blood Culture test (BC-GP) to detect bacteria, including
    antibiotic resistance markers, that may cause bloodstream infections
    (510(k) cleared; CE Mark)
--  Gram-Negative Blood Culture test (BC-GN) to detect Bacteria including
    antibiotic resistance markers, that may cause bloodstream infections
    (CE Mark)
--  Respiratory Virus Plus test (RV+) to detect multiple respiratory
    viruses which cause respiratory tract infections (510(k) cleared; CE
--  Clostridium difficile test (CDF) to detect potentially deadly C.
    difficile and identifies the 027 hypervirulent strain (510(k) cleared;
    CE Mark)
--  Enteric Pathogens test (EP) to detect and multiple bacteria, viruses
    and toxin genes which cause gastrointestinal infections (In Clinical
    Trials). Nanosphere plans to commercialize the Enteric Pathogens test
    in 2013 following receipt of the necessary regulatory approvals.

About Nanosphere, Inc.
 Nanosphere develops, manufactures and markets
an advanced molecular diagnostics platform, the Verigene System, for
multiplexed infectious disease, genetic, and ultra-sensitive protein
testing. This easy-to-use platform offers laboratories a convenient,
simple, and cost-effective solution for highly sensitive nucleic acid
and protein testing. Nanosphere is based in Northbrook, IL. 
For additional information regarding Nanosphere's infectious disease
products, please contact Nanosphere at or
About Hitachi High-Technologies Corporation
High-Technologies Corporation, headquartered in Tokyo, Japan, is
engaged in activities in a broad range of fields, including
Electronic Device Systems, Fine Technology Systems, Science & Medical
Systems, Industrial & IT Systems, and Advanced Industrial Products.
The company's consolidated sales for FY 2011 were more than $7.8
billion. For further information, please visit 
Except for historical information, the matters discussed in this
press release are "forward-looking statements" and are subject to
risks and uncertainties. Actual results could differ materially from
these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, the
following: (i) Nanosphere's ability to develop commercially viable
products; (ii) Nanosphere's ability to achieve profitability; (iii)
Nanosphere's ability to produce and market its products; (iv)
Nanosphere's ability to obtain regulatory approval of its products;
(v) Nanosphere's ability to protect its intellectual property; (vi)
competition and alternative technologies; and (vii) Nanosphere's
ability to obtain additional financing to support its operations.
Additional risks are discussed in the Company's current filings with
the Securities and Exchange Commission. Although the Company believes
the expectations reflected in such forward-looking statements are
based on reasonable assumptions, it can give no assurance that its
expectations will be attained. The forward-looking statements are
made as of the date of this press release, and we undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
Nanosphere, Inc.
Roger Moody
Chief Financial Officer 
LifeSci Advisors
Michael Rice
Founding Partner 
Press spacebar to pause and continue. Press esc to stop.